Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Silverman

Showing results (581-590 of 815) with videos related to

Pageof 82
Sort By:
Bioorganic & Medicinal Chemistry|November 25, 2010
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisTian Chen, Radhia Benmohamed, Anthony C Arvanites, et al.
ACS Chemical Neuroscience|July 9, 2014
Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosisPaul C Trippier, Kevin Tianmeng Zhao, Susan G Fox, et al.
Frontiers in Pediatrics|January 28, 2026
Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocolsGiacomo Gotti, Yael Flamand, Victoria Koch, et al.
Gastrointestinal Endoscopy|October 25, 2002
Wireless capsule endoscopy: August 2002Gregory G Ginsberg, Alan N Barkun, John J Bosco, et al.
Pediatric Blood & Cancer|December 14, 2016
A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemiaYaron Finkelstein, Traci M Blonquist, Veena Vijayanathan, et al.
Pediatric Blood & Cancer|July 2, 2011
Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosisDeborah P Waber, Jennifer Turek Queally, Lori Catania, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1996
Mullerian inhibiting substance in humans: normal levels from infancy to adulthoodM M Lee, P K Donahoe, T Hasegawa, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS"Yinan Zhang, Radhia Benmohamed, Wei Zhang, et al.
Journal of Neurointerventional Surgery|October 3, 2022
Asymptomatic carotid artery stenosis: a summary of current state of evidence for revascularization and emerging high-risk featuresHyun Woo Kim, Robert W Regenhardt, Salvatore A D'Amato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experienceJohn M Goldberg, Lewis B Silverman, Donna E Levy, et al.
Pageof 82

Showing results (581-590 of 815) with videos related to

Sort By:
Pageof 82
Bioorganic & Medicinal Chemistry|November 25, 2010
Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosisTian Chen, Radhia Benmohamed, Anthony C Arvanites, et al.
ACS Chemical Neuroscience|July 9, 2014
Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosisPaul C Trippier, Kevin Tianmeng Zhao, Susan G Fox, et al.
Frontiers in Pediatrics|January 28, 2026
Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocolsGiacomo Gotti, Yael Flamand, Victoria Koch, et al.
Gastrointestinal Endoscopy|October 25, 2002
Wireless capsule endoscopy: August 2002Gregory G Ginsberg, Alan N Barkun, John J Bosco, et al.
Pediatric Blood & Cancer|December 14, 2016
A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemiaYaron Finkelstein, Traci M Blonquist, Veena Vijayanathan, et al.
Pediatric Blood & Cancer|July 2, 2011
Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosisDeborah P Waber, Jennifer Turek Queally, Lori Catania, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1996
Mullerian inhibiting substance in humans: normal levels from infancy to adulthoodM M Lee, P K Donahoe, T Hasegawa, et al.
ACS Medicinal Chemistry Letters|March 25, 2017
Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS"Yinan Zhang, Radhia Benmohamed, Wei Zhang, et al.
Journal of Neurointerventional Surgery|October 3, 2022
Asymptomatic carotid artery stenosis: a summary of current state of evidence for revascularization and emerging high-risk featuresHyun Woo Kim, Robert W Regenhardt, Salvatore A D'Amato, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2003
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experienceJohn M Goldberg, Lewis B Silverman, Donna E Levy, et al.
Pageof 82